Dan Spiegelman
Director/Board Member chez KYVERNA THERAPEUTICS, INC.
Fortune : 863 311 $ au 31/03/2024
Profil
Daniel K.
Spiegelman was the founder of Rapidscan Pharma Solutions, Inc. (founded in 2010) where he served as the Chief Financial Officer from 2010 to 2012.
He currently holds multiple positions including Chairman at Tizona Therapeutics, Inc. (since 2019), Independent Director at Myriad Genetics, Inc. (since 2020), Independent Director at Spruce Biosciences, Inc. (since 2020), Director at Maze Therapeutics, Inc. (since 2020), Independent Director at Kyverna Therapeutics, Inc. (since 2021), Independent Director at Jiya Acquisition Corp.
(since 2020), President at Recardia Therapeutics, Inc. (since 2020), and Venture Partner at Samsara Biocapital LLC.
He has held former positions such as Chief Executive Officer at Filtini, Inc. (2009-2012), Chairman at Relypsa, Inc. (2014-2016), Director at Xcyte Therapies, Inc. (2006), Director at Omeros Corp.
(2009-2012), Independent Director at Anthera Pharmaceuticals, Inc. (2011-2014), Director at SillaJen Biotherapeutics, Inc., Independent Director at Cascadian Therapeutics LLC (2011-2018), Independent Director at Affymax, Inc. (2011-2013), Independent Director at Cyclacel Pharmaceuticals, Inc. (2004-2012), Independent Non-Executive Director at Opthea Ltd.
(2020-2024), Treasurer at Genentech, Inc. (1992-1998), and Chief Financial Officer & Senior Vice President at CV Therapeutics, Inc. (1998-2009).
He also served as the Chief Financial Officer & Executive Vice President at BioMarin Pharmaceutical, Inc. (2012-2020).
Mr. Spiegelman obtained his undergraduate degree from Stanford University in 1980 and an MBA from Stanford Graduate School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MYRIAD GENETICS, INC.
0,05% | 02/06/2023 | 40 493 ( 0,05% ) | 863 311 $ | 31/03/2024 |
OPTHEA LIMITED
-.--% | 04/04/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
| 01/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 | |
SPRUCE BIOSCIENCES, INC.
-.--% | 25/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Dan Spiegelman
| Sociétés | Poste | Début |
|---|---|---|
| MYRIAD GENETICS, INC. | Director/Board Member | 27/05/2020 |
| SPRUCE BIOSCIENCES, INC. | Director/Board Member | 09/09/2020 |
| JIYA ACQUISITION CORP. | Director/Board Member | 18/11/2020 |
| KYVERNA THERAPEUTICS, INC. | Director/Board Member | 01/04/2021 |
| Recardia Therapeutics, Inc. | President | 01/07/2020 |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Director/Board Member | 01/10/2020 |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Chairman | - |
Samsara Biocapital LLC
 Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Private Equity Investor | - |
Anciens postes connus de Dan Spiegelman
| Sociétés | Poste | Fin |
|---|---|---|
| OPTHEA LIMITED | Director/Board Member | 04/04/2024 |
| ░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░░ ░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Dan Spiegelman
| Stanford University | Undergraduate Degree |
| Stanford Graduate School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 9 |
|---|---|
| MYRIAD GENETICS, INC. | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| OMEROS CORPORATION | Health Technology |
| ANTHERA PHARMACEUTICALS, INC. | Health Technology |
| OPTHEA LIMITED | Health Technology |
| AFFYMAX, INC. | Health Technology |
| CYCLACEL PHARMACEUTICALS, INC. | Health Technology |
| SPRUCE BIOSCIENCES, INC. | Health Technology |
| KYVERNA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 13 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
| Xcyte Therapies, Inc. | Health Technology |
SillaJen Biotherapeutics, Inc.
 SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Rapidscan Pharma Solutions, Inc.
 Rapidscan Pharma Solutions, Inc. Medical/Nursing ServicesHealth Services Rapidscan Pharma Solutions, Inc. provides novel technologies for the diagnosis of disease. Its products include Regadenoson which acts as a stress agent used in the diagnosis and risk stratification of cardiovascular disease. The company was founded by Brent K. Blackburn, Daniel K. Spiegelman and Louis G. Lange in 2010 and is headquartered in Palo Alto, CA. | Health Services |
| Filtini, Inc. | |
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Health Technology |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Finance |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Commercial Services |
Jiya Acquisition Corp.
 Jiya Acquisition Corp. Financial ConglomeratesFinance Jiya Acquisition Corp. is a blank check company. The firm was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It focuses on identifying promising opportunities in the biopharmaceutical sector. The company was founded in August 2020 and is headquartered in Palo Alto, CA. | Finance |
| Recardia Therapeutics, Inc. |
